Castlight Health (CSLT) Tops Q2 EPS by 5c

Castlight Health (NYSE: CSLT) reported Q2 EPS of $0.01, $0.05 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $35.5 million versus the consensus estimate of $30.99 million.

"We made meaningful headway against our strategic plan in the second quarter, delivering strong financial results, demonstrating progress toward our goal of adding an additional health plan partner, and supporting our customers with rapid innovation during COVID-19. Over the past year, we made two major strategic decisions: our focus on health plan as a key go-to-market strategy, and investment in high-tech, high-touch solutions. Our momentum in the first half of 2020 validates these decisions, and I'm confident that Castlight is strategically well positioned in the marketplace," said Maeve O'Meara, chief executive officer of Castlight Health.

GUIDANCE:

Castlight Health sees FY2020 EPS of $0.11-$0.16, versus the consensus of ($0.13). Castlight Health sees FY2020 revenue of $127-135 million, versus the consensus of $130.8 million.

For earnings history and earnings-related data on Castlight Health (CSLT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Halozyme adds biotech executive Appelhans to its board
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance